From systems biology to P4 medicine: applications in respiratory medicine

Noell, Guillaume; Faner, Rosa; Agustí, Àlvar

doi:10.1183/16000617.0110-2017

Cited by 39 publications

(25 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is even some controversy regarding the very existence of COPD: some toplevel experts have suggested that, as advocated by the Dutch hypothesis in the early 1960's 19 , asthma and COPD should be considered as a continuum of the same condition 20 , with variations arising from the types of gene-environment interactions that participated to the development of the condition, leading to identify endotypes (pathophysiological profiles identified through biomarkers), phenotypes (clinical profiles with specific outcomes) 21 and treatable traits (individual clinical or biological characteristics that represent targets for individual treatments and can be associated differently within individuals) 22 . This forms the basis of more precise individualisation of treatment approaches, corresponding to precision or personalised medicine, respectively synonymous to or part of Personalised, Preventive, Predictive and Participative (4P) 23 .…”

Section: Definition and Diagnosismentioning

confidence: 99%

GOLD Reports on Chronic Obstructive Pulmonary Disease (COPD): Evolutions, Revolutions and Controversies

Roche¹,

Criner²,

Vogelmeier³

2021

BRN

View full text Add to dashboard Cite

Twenty years after its start, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) continues to evolve and remains a source of progress and controversy in the area of chronic obstructive pulmonary disease (COPD) management. Major changes in the definition have occurred, influenced by progress in our understanding of the natural history of COPD. Similarly, while few new beneficial pharmacological classes have been developed, the way available medications should be used has significantly evolved. The burden of comorbidities is now well recognised, COPD being most often part of a multimorbid chronic condition. The role of non-pharmacological approaches has increased with a growing interest in complex interventions such as "integrated care" or "disease management". Instrumental support/interventions have also been an area of progress with new encouraging data on long-term non-invasive ventilation or endoscopic interventions. Altogether, COPD research is increasingly dynamic, and will most certainly solve future current debates and uncertainties. (BRN Rev. 2019;5(2):104-119)

show abstract

Section: Definition and Diagnosismentioning

confidence: 99%

GOLD Reports on Chronic Obstructive Pulmonary Disease (COPD): Evolutions, Revolutions and Controversies

Roche¹,

Criner²,

Vogelmeier³

2021

BRN

View full text Add to dashboard Cite

show abstract

“…Such practices call for tailored education programs and continuous, complimentary training for hospital personnel as well as for systemic scientists. 36,148,149…”

Section: Concluding Remarks and Outlookmentioning

confidence: 99%

Network and Systems Medicine: Position Paper of the European Collaboration on Science and Technology Action on Open Multiscale Systems Medicine

Comte

Baumbach

Benis

et al. 2020

Network and Systems Medicine

View full text Add to dashboard Cite

Introduction: Network and systems medicine has rapidly evolved over the past decade, thanks to computational and integrative tools, which stem in part from systems biology. However, major challenges and hurdles are still present regarding validation and translation into clinical application and decision making for precision medicine. Methods: In this context, the Collaboration on Science and Technology Action on Open Multiscale Systems Medicine (OpenMultiMed) reviewed the available advanced technologies for multidimensional data generation and integration in an open-science approach as well as key clinical applications of network and systems medicine and the main issues and opportunities for the future. Results: The development of multi-omic approaches as well as new digital tools provides a unique opportunity to explore complex biological systems and networks at different scales. Moreover, the application of findable, applicable, interoperable, and reusable principles and the adoption of standards increases data availability and sharing for multiscale integration and interpretation. These innovations have led to the first clinical applications of network and systems medicine, particularly in the field of personalized therapy and drug dosing. Enlarging network and systems medicine application would now imply to increase patient engagement and health care providers as well as to educate the novel generations of medical doctors and biomedical researchers to

show abstract

“…New omics-based approaches seem to be more appropriate for assessing the heterogeneity of asthma; however, they do not consider BMI to be a relevant factor [30]. When dealing with complex and heterogeneous diseases such as asthma and obesity, our traditional reductionist approach should give way to other strategies that, based upon systems biology, provide us with wider perspectives [31,32]. In fact, Gómez-Llorente et al [33] review the pathophysiological mechanisms shared by obesity and asthma and suggest that the relationship between both conditions would also imply other systemic inflammatory syndromes, insulin resistance, and alterations in microbiota.…”

Section: Obesity and Asthma: The Chicken Or The Egg? Clinical Insightmentioning

confidence: 99%

Obesity and Asthma: Key Clinical Questions

García‐Río¹,

Alvarez-Puebla²,

Esteban-Gorgojo³

et al. 2019

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Obesity is an asthma common comorbidity and is associated not only with its development, but also with a poorer control and higher severity of it. Recent prospective evidence supports the idea that body weight gain precedes the development of asthma, but the debate is far from over. The objective of this document is to conduct a systematic review of 3 clinical questions related to asthma and obesity: 1. Obesity and asthma: the chicken or the egg? Clinical insights from epidemiological and phenotypes studies. 2. Is obesity a confounding factor in the diagnosis and management of asthma and especially in severe or difficult-to-control asthma? 3. How obese asthma subjects respond to pharmacological treatments, and to biological drugs? Do we have effective specific interventions?. Revised epidemiological, pathological and mechanistic evidence combined with data from the intervention clinical trials do not allow us to clearly state that obesity is an asthma-causative agent. However, the complexity and heterogeneity of these two illnesses make several clinical scenarios possible. Furthermore, the diagnosis of asthma in an obese patient represents an additional clinical challenge. Physicians need to be aware of the confounding effects created by the greater symptomatic perception, the alterations of lung function and the different comorbidities that the obese subjects present. A exhaustive phenotyping of the obese asthma patient should lead us to a rational therapeutic plan, including both, the pharmacological approach and anti-obesity specific therapies including a combined plan of diet and exercise and in extreme cases, bariatric surgery.

show abstract

From systems biology to P4 medicine: applications in respiratory medicine

Cited by 39 publications

References 127 publications

GOLD Reports on Chronic Obstructive Pulmonary Disease (COPD): Evolutions, Revolutions and Controversies

GOLD Reports on Chronic Obstructive Pulmonary Disease (COPD): Evolutions, Revolutions and Controversies

Network and Systems Medicine: Position Paper of the European Collaboration on Science and Technology Action on Open Multiscale Systems Medicine

Obesity and Asthma: Key Clinical Questions

Contact Info

Product

Resources

About